Patents by Inventor Norbert Wiedemann

Norbert Wiedemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20240010731
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 11, 2024
    Applicants: Debiopharm International S.A., Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20220096436
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143, or another IAP antagonist, and a therapeutically effective amount of nivolumab, for the treatment of cancer, are provided.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 31, 2022
    Applicant: Debiopharm International S.A.
    Inventors: Sergio Adrian Szyldergemajn Altman, Grégoire Vuagniaux, Norbert Wiedemann, Daniela Purcea
  • COMBINATION TREATMENT OF HIV INFECTIONS
    Publication number: 20220016079
    Abstract: The present invention provides combination therapies for the treatment of HIV. The combination therapies of the present invention are aimed to reverse HIV latency and ultimately cure the disease. The combination therapies of the invention involve the use of an IAP inhibitor and the use of an immune checkpoint inhibitor.
    Type: Application
    Filed: November 26, 2019
    Publication date: January 20, 2022
    Applicant: Debiopharm International S.A.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20210198365
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • COMBINATION ANTI CANCER THERAPY WITH AN IAP ANTAGONIST AND AN ANTI PD-1 MOLECULE
    Publication number: 20210093645
    Abstract: Disclosed is the use of an IAP antagonist for pretreating a human subject diagnosed with a cancer to enhance the likelihood that a subsequent treatment with an anti-PD-1 molecule results in an anti-cancer response or to enhance the responsiveness of the subject's cancer to the subsequent treatment with the anti-PD-1 molecule. Also encompassed are methods of treatment of a subject's cancer, the methods comprising pretreatment of the subject with an IAP antagonist and subsequent treatment of the subject with an anti-PD-1 molecule.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 1, 2021
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Bruno Gavillet, Sergio Adrian Syldergemajn Altman